Message From the Editor-in-Chief
Circulation Reports Is Entering Its 7th Year With an Impact Factor
2025 年 7 巻 1 号 p. 1-3
詳細
2025 年 7 巻 1 号 p. 1-3
Dear Colleagues,
Welcome to the first issue of the Circulation Reports (Circ Rep) in 2025. On January 10, 2019, Circ Rep, a sister journal of the Circulation Journal, was launched as an official Journal of the Japanese Circulation Society. During those 6 years, Circ Rep has published many interesting papers, not only from Japan but also from around the world. On March 12, 2021, all papers published in Circ Rep became searchable in PubMed Central®, a great achievement by the editorial team. On July 22, 2024, ClarivateTM selected Circ Rep for inclusion in the Web of ScienceTM, the world’s most trusted publisher-independent global citation database. Articles published after 2022, beginning with Volume 4 Number 1 (2022), are included in the Emerging Sources Citation Index. Thus, it is expected that Circ Rep will obtain an impact factor in the summer of 2025.
Here, I take an opportunity to summarize the progress of Circ Rep in 2024.
Figure 1 shows the number of manuscripts submitted, approximately 15 per month. As of November 14, 2024, 148 manuscripts had been submitted: 68.9% were de novo submissions and 31.1% were transferred from Circulation Journal. Figure 2 shows the types of submitted manuscripts. Clinical Investigations and Images in Cardiovascular Medicine are major categories. Circ Rep published 5 Protocol Papers and 2 Statements/Opinions, which are unique categories of this journal. Figure 3 shows the countries from which manuscripts were submitted. Although submissions from Japan dominated, the Journal received manuscripts from Austria, Germany, Korea and the United Kingdom.
Number of manuscripts/month submitted in 2024.
Types of manuscripts submitted in 2024.
Countries from which manuscripts were submitted in 2024.
Currently, the acceptance rate is 69.3%. Most of the manuscripts transferred from Circulation Journal are accepted without delay after the Editor-in-Chief has carefully checked the revised manuscript and the author’s replies to the original reviewers. In 2024, the average time from submission to acceptance was 25.1 days, and the average time from acceptance to advance online publication was 33.3 days. The editorial team continues to work on minimizing the time from submission to publication.
Circ Rep published 95 excellent papers in 2024. The top 10 papers most frequently viewed are summarized in the Table.
Top 10 Frequently Viewed Papers in Circulation Reports
| Rank | Access* | Paper authors and title |
|---|---|---|
| 1 | 2,264 | Kono Y, Sakurada K, Iida Y, Iwata K, Kato M, Kamiya K, et al.; on behalf of J-Proof HF Scientific Committee. Real- world evidence of feasible assessment and intervention in cardiovascular physical therapy for older patients with heart failure: Insight from the J-Proof HF of the Japanese Society of Cardiovascular Physical Therapy. Circ Rep 2024; 6: 441–447, doi:10.1253/circrep.CR-24-0058. |
| 2 | 1,991 | Tsutsui H. Tribute to Dr. Tomomi Ide, MD, PhD. Circ Rep 2024; 6: 238–240, doi:10.1253/circrep.CR-66-0017. |
| 3 | 1,518 | Yasuda R, Osawa I, Goto T, Hasegawa K, Fifer MA, Tower-Rader A, et al. Mortality after alcohol septal ablation vs. septal myectomy in patients with obstructive hypertrophic cardiomyopathy. Circ Rep 2024; 6: 74–79, doi:10.1253/ circrep.CR-23-0101. |
| 4 | 1,258 | Fujisue K, Ito M, Matsuzawa Y, Arima Y, Takashio S, Sueta D, et al. Open-label, single-center, single-arm study evaluating the efficacy and safety of elobixibat for chronic constipation in patients with heart failure. Circ Rep 2024; 6: 55–63, doi:10.1253/circrep.CR-23-0099. |
| 4 | 1,258 | Horio T, Iwashima Y, Yoshiyama M, Fukuda D, Hasegawa T, Fujimoto K. Clinical benefit of sacubitril/valsartan for hypertensive patients in daily practice and predictors of its antihypertensive effect. Circ Rep 2024; 6: 248–254, doi:10.1253/circrep.CR-24-0017. |
| 6 | 1,222 | Suzuki S, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, et al. Patient outcomes in very elderly patients with non-valvular atrial fibrillation: ANAFIE Registry. Circ Rep 2024; 6: 283–293, doi:10.1253/circrep.CR-24-0061. |
| 7 | 1,195 | Ishihara T, Kuramitsu S, Matsuo H, Horie K, Takashima H, Terai H, et al.; on behalf of the J-CONFIRM Investigators. Sex differences in 5-year outcomes after deferral of revascularization following physiological coronary assessment. Circ Rep 2024; 6: 19–27, doi:10.1253/circrep.CR-23-0100. |
| 8 | 1,099 | Miyawaki N, Ishizu K, Shirai S, Miyahara K, Yamamoto K, Suenaga T, et al. Impact of cognitive impairment on long- term outcomes after transcatheter aortic valve implantation. Circ Rep 2024; 6: 357–365, doi:10.1253/circrep.CR-24- 0078. |
| 9 | 1,022 | Ishihara Y, Ishizawa M, Noma T, Ohara M, Tani R, Kurashita G, et al. Diagnostic performance of an automated blood pressure monitor with an irregular heartbeat algorithm designed to detect atrial fibrillation. Circ Rep 2024; 6: 110–117, doi:10.1253/circrep.CR-24-0008. |
| 9 | 1,022 | Yuguchi T, Nakajima K, Takaoka H, Shimokawa T. Usefulness of clinical frailty scale for comprehensive geriatric assessment of older heart failure patients. Circ Rep 2024; 6: 127–133, doi:10.1253/circrep.CR-24-0009. |
*The number of times the online journal bibliographic information has been viewed over the past 1 year.
It is on this basis that I and the editorial team greatly anticipate that Circ Rep will obtain its initial impact factor. I acknowledge all the associate editors and reviewers for their excellent, quick work and commitment to reviewing manuscripts. I also thank the secretaries in the editorial office for their continuous support. I hope that more and more manuscripts will be submitted from all over the world this year.
